Brief: Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial Of FT819 For The Treatment Of Lupus Nephritis
14/08/2026 12:16
BRIEF-Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial Of FT819 For The Treatment Of Lupus Nephritis Aug 14 (Reuters) - Fate Therapeutics Inc FATE.O:
FATE THERAPEUTICS INITIATES POTENTIALLY REGISTRATIONAL RECLAIM-LN CLINICAL TRIAL OF FT819 FOR THE TREATMENT OF LUPUS NEPHRITIS
FATE THERAPEUTICS - PATIENTS TO RECEIVE SINGLE 900 MILLION-CELL DOSE OF FT819; PRIMARY ENDPOINT AT WEEK 26
Source text: ID:nGNX3VKK1W
Further company coverage: FATE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fate Therapeutics
See all newsBrief: Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial Of FT819 For The Treatment Of Lupus Nephritis
Fate Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Fate Therapeutics Q2 loss narrows as expenses fall, revenue rises
Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview
Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview